فهرس الدراسات بحسب الترتيب الأبجدي
فهرس:
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
BACKGROUND Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 inhibitor, reduced the risk of major adverse cardiovascular events in patients with type...
التفاصيل
Effect of telmisartan on kidney function in patients with chronic kidney disease: an observational study
Background: Globally the burden of chronic kidney disease (CKD) is rising, an important cause of death and loss of disability-adjusted life years. Activation of the renin-angiotensin-aldosterone system is involved in its pathogenesis. The aim of...
التفاصيل
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infectionq
Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. This Clinical Practice Guideline presents updated recommendations for the optimal management of...
التفاصيل
Empagliflozin/Linagliptin: A Review in Type 2 Diabetes
Abstract Empagliflozin/linagliptin (Glyxambi) is a once-daily sodium glucose co-transporter type 2 (SGLT2) inhibitor and dipeptidyl peptidase (DPP)-4 inhibitor fixeddose combination product that is approved in the USA as an adjunct to diet and exercise in...
التفاصيل
Effect of Alpha-Lipoic Acid on Clinical and Neurophysiologic Recovery of Carpal Tunnel Syndrome: A Double-Blind, Randomized Clinical Trial
The objective of our study was to examine the effect of alpha-lipoic acid (ALA) on clinical and neurophysiologic outcomes after surgery for idiopathic carpal tunnel syndrome (CTS). We conducted a randomized, double-blind, placebo-controlled clinical trial in...
التفاصيل